Theravance Biopharma Inc. recently presented positive data from multiple Vibativ studies at the ASM Microbe 2017 Meeting, the annual gathering of the American Society for Microbiology held in New Orleans.
Vibativ, the company’s proprietary FDA-approved antibiotic, was shown to have greater in vitro potency than comparable commercialized antibiotics against Staphylococcus aureus (S. aureus) pathogens.
"We continue to work aggressively to generate compelling data to differentiate Vibativ from other available antibiotics in some of the health care industry's most troubling and difficult-to-treat infection types," Frank Pasqualone, chief commercial operations officer at Theravance Biopharma, said in a statement. "To this end, these latest data add to the impressive collection of research that demonstrates that Vibativ has greater in vitro potency against a variety of MRSA and MDR infections than many well-known antibiotic products."
In an environment clouded by the challenges of antibiotic resistance, Pasqualone believes the in vitro potency of Vibativ, coupled with its demonstrated bactericidal activity, provides clinicians an important antibiotic treatment option for some of their most challenging cases.
Alerts Sign-up